Off-Label GLP-1 Use Surges in Young Children

Prescribing of GLP-1 receptor agonists to children aged 8 to 11 years with obesity experienced a dramatic surge, increasing 310-fold between 2019 and the study period, according to a large cross-sectional analysis. This significant rise in off-label use occurred despite the absence of U.S. Food and Drug Administration (FDA) approval for these medications in children under 12 years of age. The analysis, which examined data from over 3.5 million children, highlights a growing trend of utilizing these drugs for pediatric weight management outside of their officially sanctioned indications. GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda), were initially developed and approved for type 2 diabetes management in adults and subsequently for chronic weight management in adults and adolescents aged 12 and older. The medications work by mimicking the action of the GLP-1 hormone, which helps regulate appetite and blood sugar levels, leading to reduced food intake and weight loss. The study's findings indicate a substantial shift in clinical practice, with healthcare providers increasingly turning to these powerful medications for younger children facing obesity. This trend raises important questions regarding the long-term safety and efficacy of GLP-1 receptor agonists in this younger demographic, for whom extensive clinical trials have not yet been conducted. The lack of FDA approval for this age group means that prescribing decisions are made based on physician judgment and available evidence from adult and adolescent studies, rather than specific pediatric data. Experts have expressed concerns about potential side effects, including gastrointestinal issues, and the need for careful monitoring and comprehensive lifestyle interventions to accompany pharmacotherapy. The analysis did not specify the exact GLP-1 receptor agonists prescribed, but the class includes widely recognized medications used for weight loss. The surge in prescriptions suggests a perceived unmet need in pediatric obesity treatment, potentially driven by the effectiveness observed in older populations and the increasing prevalence of childhood obesity. Further research is warranted to establish appropriate dosing, monitor for adverse events, and determine the long-term health outcomes associated with the use of GLP-1 receptor agonists in children aged 8 to 11. The study's methodology, relying on a large dataset, provides a robust snapshot of prescribing patterns, underscoring the urgency for continued investigation and potential regulatory review as this trend evolves.